Communiqués Annexon, Inc.

Actions

ANNX

US03589W1027

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 29/09/2026			Varia. 5j.	Varia. 1 janv.
4,130 ^USD	+2,99%		-1,20%	-17,73%

24/09	Annexon, Inc. annonce des présentations orales sur le vonaprument lors de la 59e réunion scientifique annuelle de la Retina Society	CI
12/08	Transcript : Annexon, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Communiqués

24/09	Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting	GL
24/09	Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting	AQ
16/09	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	GL
02/09	Annexon to Participate in Upcoming September Investor Conferences	GL
02/09	Annexon to Participate in Upcoming September Investor Conferences	AQ
18/08	Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4)	AQ
17/08	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	GL
12/08	Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones	GL
12/08	Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study	GL
10/08	Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors	GL
06/08	Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week	GL
06/08	Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week	AQ
30/07	Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance	GL
16/07	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	GL
14/07	Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026	GL
16/06	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	GL
27/05	Annexon to Participate in Upcoming June Investor Conferences	GL
19/05	Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4)	AQ
18/05	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	GL
08/05	Annexon : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones	GL
06/05	Annexon to Present at the Bank of America Securities Health Care Conference 2026	GL
08/04	Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference	GL
08/04	Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ
30/03	Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones	GL